CDNA — CareDx, Inc

CareDx (CDNA) Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: $100.1 million, a 21% year-over-year increase.
• Testing Services Revenue: $72.2 million, up 19% with approximately 50,300 tests delivered (13% growth).
• Adjusted EBITDA: $15.3 million, more than double from Q3 last year.
• Gross Profit: $70.9 million, with gross margins improving to 70.9%.
• Cash Collections: $119 million, with record collections of $90 million from testing services.
• Share Repurchases: 2 million shares repurchased at an average price of $12.87; approximately 9% of shares outstanding repurchased year-to-date.
• Guidance Raised: Full-year 2025 revenue guidance increased to $372 million - $376 million; adjusted EBITDA guidance raised to $35 million - $39 million.

2. Strategic Updates and Business Highlights

• Leadership Appointments: Suresh Gunasekaran and Dr. Jeff Teuteberg joined the Board and as Chief Medical Officer, respectively, enhancing CareDx's expertise in transplantation.
• Product Launches: Introduced HistoMap Kidney, a tissue-based molecular test aimed at improving kidney transplant care, expected to be commercially available in late 2026.
• Operational Improvements: Significant advancements in revenue cycle management (RCM), with a 600 basis point reduction in claims rejection rates and a 200% increase in appeals volume.
• EPIC Integration: Successful pilot at Boston Children's Hospital, with plans to expand to 40 centers by 2026, anticipating a 10% volume uplift post-implementation.

3. Forward Guidance and Outlook

• Q4 2025 Expectations: Revenue projected between $101 million - $105 million, with testing volume expected to range from 52,000 to 54,000 tests.
• ASP Guidance: Anticipated average revenue per test of $1,400 - $1,420, including $4 million - $6 million from prior period collections.
• Long-term Outlook: Confidence in continued growth driven by RCM improvements and product adoption, though specific guidance for 2026 will be provided after finalization of the LCD policy.

4. Challenges and Points of Concern

• Transplant Volume Trends: Overall transplant volumes have remained flat year-over-year, particularly in kidney transplants, which may impact future testing volumes.
• Regulatory Risks: Potential headwinds from the draft LCD policy for molecular testing, which could limit coverage for certain tests, although management remains optimistic about maintaining clinician utilization.
• Market Dynamics: Concerns about media scrutiny affecting transplant practices and potential impacts on kidney transplant volumes.

5. Notable Q&A Insights

• Durability of ASPs: Management expressed confidence in the sustainability of average selling prices (ASPs) due to strong cash collections and RCM success.
• Integration Impact: Early results from EPIC Aura integration show promising improvements in order turnaround times and specimen holds, suggesting positive implications for future volumes.
• IOTA Program: There are expectations for growth in kidney transplant volumes as the IOTA program progresses, despite current media-related hesitancy among transplant centers.
• SHORE Study Impact: The SHORE registry study has positively influenced the adoption of HeartCare products, with ongoing analyses expected to further validate their use.

Overall, CareDx reported strong financial performance in Q3 2025, bolstered by strategic initiatives and leadership changes, while facing challenges related to transplant volume trends and regulatory scrutiny.